329 related articles for article (PubMed ID: 15761259)
1. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG
Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259
[TBL] [Abstract][Full Text] [Related]
2. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma.
Hillman GG; Xu M; Wang Y; Wright JL; Lu X; Kallinteris NL; Tekyi-Mensah S; Thompson TC; Mitchell MS; Forman JD
Hum Gene Ther; 2003 May; 14(8):763-75. PubMed ID: 12804139
[TBL] [Abstract][Full Text] [Related]
3. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
[TBL] [Abstract][Full Text] [Related]
4. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
5. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
6. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
7. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
[TBL] [Abstract][Full Text] [Related]
8. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
[TBL] [Abstract][Full Text] [Related]
9. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.
Lu X; Kallinteris NL; Li J; Wu S; Li Y; Jiang Z; Hillman GG; Gulfo JV; Humphreys RE; Xu M
Cancer Immunol Immunother; 2003 Oct; 52(10):592-8. PubMed ID: 12827305
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
11. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
12. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.
Lu X; Wu S; Blackwell CE; Humphreys RE; von Hofe E; Xu M
Immunology; 2007 Feb; 120(2):207-16. PubMed ID: 17116173
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
14. pRB is required for interferon-gamma-induction of the MHC class II abeta gene.
Zhu X; Pattenden S; Bremner R
Oncogene; 1999 Sep; 18(35):4940-7. PubMed ID: 10490828
[TBL] [Abstract][Full Text] [Related]
15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
16. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
[TBL] [Abstract][Full Text] [Related]
17. Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC.
Panelli MC; Wang E; Shen S; Schluter SF; Bernstein RM; Hersh EM; Stopeck A; Gangavalli R; Barber J; Jolly D; Akporiaye ET
Cancer Immunol Immunother; 1996 Feb; 42(2):99-107. PubMed ID: 8620527
[TBL] [Abstract][Full Text] [Related]
18. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
19. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
20. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria.
YaƱez DM; Manning DD; Cooley AJ; Weidanz WP; van der Heyde HC
J Immunol; 1996 Aug; 157(4):1620-4. PubMed ID: 8759747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]